Ungated Post | 06 Mar 2020
Making cells better: Complex challenges drive innovation in cell and gene therapy manufacturing
The processes required for C> manufacture are wholly new and extremely complex. As production and delivery of these new therapies to patients are still nascent, biopharmaceutical companies will need to harness new technological advances and innovate continuously in the manufacturing process.
Large capital investments in the industry are likely to bring breakthroughs in the coming years that will standardise processes, simplify delivery logistics, boost efficiency, and increase competition.
Our Thought Leadership team produces original, evidence-based research made accessible to decision-makers and opinion leaders. Principals for this project included:
Oxford Economics’ team is expert at applying advanced economic tools that provide valuable insights into today’s most pressing business, financial, and policy issues.
To find out more about our capabilities, contact:
EMEA
Paul Donnelly
020 3910 8000
Email
Americas
Jeffrey Klonoski
+1 646 503 3048
Email
Asia
Christie Tang
+852 3974 8841
Email
Related Services
Post
Delivering Value: The Economic Impact of the Civil Nuclear Industry
The study suggests the civil nuclear industry supports a £16.1 billion contribution to UK GDP, 211,500 jobs, and £7.1 billion in tax revenues. 24% occurs in the North West and 16% in the South West.
Find Out More
Post
Innovation Index: Are You Prepared to Shift from Survival to Growth?
Oxford Economics and NTT Data fielded a survey of 1,000 North American business and IT executives in 2022 to uncover future strategies to mitigate disruption.
Find Out More
Post
Reinventing for growth in a changing media landscape
Oxford Economics partnered with Accenture to survey 6,000 consumers around the world about their media and entertainment habits, experiences, and preferences.
Find Out More